The Verdict From ALLHAT—Thiazide Diuretics Are the Preferred Initial Therapy for Hypertension

dc.contributor.authorAppel, Lawrence J.
dc.date.accessioned2019-08-14T15:01:53Z
dc.date.available2019-08-14T15:01:53Z
dc.date.issued2002
dc.description.abstractQuite simply, the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is one of the most important trials of antihypertensive therapy. For decades, experts have passionately debated which class of drugs should be initial therapy for hypertension. Resolution of this issue, which has enormous clinical, public health, and economic implications, comes at a time of intense pressure to reduce health care costs while improving clinical outcomes. In this setting, the ALLHAT results, reported in this issue of THE JOURNAL, are particularly noteworthy, because there is no cost-quality tradeoff; the most effective therapy was also the least expensive.
dc.description.urihttp://jama.ama-assn.org/cgi/content/full/288/23/3039
dc.identifierhttps://doi.org/10.13016/4lqk-sieq
dc.identifier.citationAppel, Lawrence J. (2002) The Verdict From ALLHAT—Thiazide Diuretics Are the Preferred Initial Therapy for Hypertension. JAMA, 288 (23). pp. 3039-3042.
dc.identifier.otherEprint ID 1255
dc.identifier.urihttp://hdl.handle.net/1903/23100
dc.subjectPharmacotherapy
dc.subjectHypertension
dc.subjectantihypertensive therapy
dc.subjecthypertension
dc.subjecthealth care costs
dc.titleThe Verdict From ALLHAT—Thiazide Diuretics Are the Preferred Initial Therapy for Hypertension
dc.typeArticle

Files